Assessing the History and Value of Human Genome Sciences Received: May 23, 2013

Total Page:16

File Type:pdf, Size:1020Kb

Assessing the History and Value of Human Genome Sciences Received: May 23, 2013 Case Study Assessing the history and value of Human Genome Sciences Received: May 23, 2013. Accepted: September 3, 2013. Laura M. McNamee is Research Associate in the Center for Integration of Science and Industry and Adjunct Assistant Professor of Natural and Applied Science at Bentley University. Her research focuses on patterns of sustaining and disruptive innovation in biotechnology, the impact of technology life cycles on drug development, and business models for the biotechnology industry. Fred D. Ledley is Director of the Center for Integration of Science and Industry and a Professor in the Department of Natural and Applied Sciences and Department of Management and at Bentley University. He has served on the faculties of the Baylor College of Medicine and Howard Hughes Institute, and also as a founder and senior executive of several biotechnology companies in gene therapy and personalized medicine. His research focuses on the interface between science and business, as well as strategies for accelerating the translation of scientific discoveries to create public value. ABSTRACT Human Genome Science (HGS) aspired to dominate the emergent field of genomics by discovering expressed gene sequences and developing therapeutic and diagnostic products based on proprietary genes. While HGS’ accomplishments fell short of their own lofty expectations, by the time HGS was acquired by GlaxoSmithKline, the company had extensive intellectual property and had launched a product with >$1 billion market potential. Nevertheless, HGS’ acquisition price was less than the total capital investments in the company. This work examines HGS’ history and accomplishments in the context of the business plan described by the company at their IPO. We focus specifically on the company’s valuation over time, which was highly correlated with general market indices, but negatively correlated with metrics of technical or clinical progress. The history of HGS points to the challenge of accounting for the value created by a science-based business plan. Earnings-based metrics, present value calculations, and “fair value” assessments did not account for HGS’ progress in executing their stated business plan. This work highlights the critical need for accounting practices that credit value to the progress of translational science and enable investors to profit from such investments. Journal of Commercial Biotechnology (2013) 19(4), 3–10. doi: 10.5912/jcb.619 Keywords: Genomics; drug development; value; investment; biotechnology; accounting GlaxoSmithKline (GSK) in 2012 for $3.6 billion,1 the INTRODUCTION company could claim many accomplishments, but had uman Genome Sciences (HGS) was not a ultimately failed to fulfill its own lofty expectations. The company with normal ambitions. At its found- story of HGS is an exemplar of the ambitions and aspi- ing in 1992, HGS aspired to dominate the newly rations of the biotechnology industry in general, and its Hemergent field of geno mics by being the first to sequence denouement provides insight into the challenges that and patent all of the genes expressed from the human prevent this industry from fulfilling its promise. What genome and develop a pipeline of therapeutic and diag- happened to HGS? What was its value? What can the nostic products based on these genes. The company’s biotechnology industry learn that will be of value in the outsized ambitions were advertised in elaborate annual future? reports, which featured Greek gods and saints as met- aphors for the company’s search for knowledge and fight against disease. By the time HGS was acquired by A SHORT HISTORY The history of HGS begins with Craig Venter’s ambitious Correspondence: Fred D. Ledley, Bentley University. proposition that all of the genes expressed by the human Email: [email protected] genome could be discovered by shotgun sequencing of OCTOBER 2013 I VOLUME 19 I NUMBER 4 3 expressed messenger RNA sequences, termed “expressed provided HGS with financial and technical support, and sequence tags” (EST). In 1992, two investors, Alan integrated HGS’ intellectual property and methods into Walton and Walter Steinberg, who were among the their partner’s internal development programs. When first to recognize the commercial potential of Venter’s the consortium agreement expired in June 2001, an HGS approach, arranged for the founding of two organi- press release noted that “Consortium members have zations. The Institute for Genetic Research (TIGR), a identified approximately 460 research programs for the non-profit scientific enterprise led by Venter, would creation of small molecule, protein, and antibody drugs, undertake high-throughput sequencing of ESTs. Human involving about 280 different genes. We believe there is Genome Sciences (HGS), a commercial enterprise led substantial value in these partnerships” by William Hazeltine, would provide financial support The first clinical trials with proteins discovered for TIGR, and have commercial rights to its discoveries. through EST sequencing began in the late 1990s. In Within a year, HGS completed a landmark partnership 1995, HGS initiated clinical development of repifermin, with SmithKline Beecham, which provided additional a recombinant Keratinocyte Growth Factor-2 protein capital investment, research funding, and experience in (KGF-2), to accelerate the healing of ulcers. In 1998, it drug discovery and development. initiated clinical trials for mirostipen, a recombinant In 1993, HGS filed for its IPO. The Company’s S-1 Myeloid Progenitor Inhibitory Factor-1 protein (MPIF-1) filing described the company’s goals as: “The Company’s for the treatment of neutropenia. Also in 1998, a third principal objective is to discover rapidly and obtain pro- candidate product, a gene therapy incorporating the prietary rights to a substantial portfolio of novel genes gene sequence for Vascular Endothelial Growth Factor-2 and to commercialize products based on those genes protein (VEGF-2) to treat atherosclerosis, was spun either alone or in collaboration with corporate part- out to a newly formed gene therapy company, Vascular ners.”2 The strategy, as described in the S-1 filing, was “to Genetics. None of these trials would proceed beyond identify rapidly the majority of the genes that comprise Phase 2 (Table 1). In addition to using newly discovered the human genome through partial sequencing and to gene sequences and their gene products as therapeutic select for further development those genes which have entities, HGS entered into a partnership in 1999 with potential commercial value.” Already by 1993, the S-1 Cambridge Antibody Technology to develop mono- stated that “…the Company believes it has, together with clonal antibodies that would inhibit the function of the TIGR, identified approximately 25,000 human genes gene products discovered by HGS. (including approximately 20,000 novel genes) of a total As the stock market started its exuberant climb of 50,000–100,000 genes believed to exist.”2 in 1999 and Craig Venter joined Francis Collins at the The relationship between TIGR and HGS was ter- White House to announce completion of the Human minated in June 1997, and Venter turned his attention Genome Project in 2000, HGS was well positioned to to sequencing the entire human genome through his capitalize on investor enthusiasm for genomics. The association with a new company, Celera Genomics. By company had more than 100 issued patents, a robust then, more than 162,000 non-overlapping ESTs had clinical development pipeline, multiple corporate part- been sequenced. Of these ESTs, 82% were thought to ners, and a high profile in the scientific and business represent the transcripts of previously unknown genes.3 community. The company raised a total of $1.4 billion HGS’ 1998 annual report summarized its gene discov- dollars through two secondary offerings in 2000, and ery efforts thus: “Between 1993 and 1995, HGS’ scientists closed Q3 2000 with a market capitalization in excess isolated messenger RNAs corresponding to what is esti- of $8.5 billion. This financing bonanza allowed HGS to mated to be more than 95 percent of all human genes.”4 grow to over 1100 employees and purchase Principia The report also described an emphasis on a “functional Pharmaceutical for $150 million. This acquisition pro- genomics” program, which included gene expression vided HGS with an expanded clinical pipeline of 20 profiling to “analyze gene expression of each of the more candidate products based on existing, patent-expiring than 11,000 newly discovered secreted protein genes” biological products as well as a technology applicable to as well as “high-throughput, robotic-cloning method pharmaceuticalizing gene products identified through to produce small amounts of each newly discovered HGS’ gene discovery platform. Despite its formidable secreted protein” and the analysis of 12,000 genes using technical position and strengthening clinical pipeline, this method.4 the end of the “dot.com” bubble caused HGS’ stock to On the business development front, HGS assembled collapse. By the end of 2002, the company’s market capi- a “Human Gene Consortium” of pharmaceutical compa- talization had dropped to $1.1 billion, only 13% of its nies including SmithKline Beecham, Schering-Plough, peak value (Figure 1a). Takeda Chemical, Synthelabo, and Merck KGaA, to part- HGS had limited revenues from 1993–2008, mostly ner in drug discovery and development. These companies from research relationships, and continued to invest 4 JOURNAL OF COMMERCIAL BIOTECHNOLOGY
Recommended publications
  • Current Therapies for Chronic Hepatitis C
    Southern Illinois University Edwardsville SPARK Pharmacy Faculty Research, Scholarship, and Creative Activity School of Pharmacy 1-2011 Current Therapies for Chronic Hepatitis C McKenzie C. Ferguson Southern Illinois University Edwardsville, [email protected] Follow this and additional works at: https://spark.siue.edu/pharmacy_fac Part of the Pharmacy and Pharmaceutical Sciences Commons Recommended Citation Ferguson, McKenzie C., "Current Therapies for Chronic Hepatitis C" (2011). Pharmacy Faculty Research, Scholarship, and Creative Activity. 4. https://spark.siue.edu/pharmacy_fac/4 This Article is brought to you for free and open access by the School of Pharmacy at SPARK. It has been accepted for inclusion in Pharmacy Faculty Research, Scholarship, and Creative Activity by an authorized administrator of SPARK. For more information, please contact [email protected],[email protected]. Chronic Hepatitis C & Current Therapies 1 Review of Chronic Hepatitis C & Current Therapies Reviews of Therapeutics Pharmacotherapy McKenzie C. Ferguson, Pharm.D., BCPS From the School of Pharmacy, Southern Illinois University Edwardsville, Department of Pharmacy Practice, Edwardsville, Illinois. Address for reprint requests : Southern Illinois University Edwardsville School of Pharmacy 220 University Park Drive, Ste 1037 Edwardsville, IL 62026-2000 Email: [email protected] Keywords : hepatitis C, HCV, ribavirin, interferon, peginterferon alfa-2a, peginterferon alfa-2b, albinterferon, taribavirin, telaprevir, therapeutic efficacy, safety The author received no sources of support in the form of grants, equipment, or drugs. Chronic Hepatitis C & Current Therapies 2 ABSTRACT Hepatitis C virus affects more than 180 million people worldwide and as many as 4 million people in the United States. Given that most patients are asymptomatic until late in disease progression, diagnostic screening and evaluation of patients that display high-risk behaviors associated with acquisition of hepatitis C should be performed.
    [Show full text]
  • Interferon-Based Biopharmaceuticals: Overview on the Production, Purification, and Formulation
    Review Interferon-Based Biopharmaceuticals: Overview on the Production, Purification, and Formulation Leonor S. Castro 1,†, Guilherme S. Lobo 1,†, Patrícia Pereira 2 , Mara G. Freire 1 ,Márcia C. Neves 1,* and Augusto Q. Pedro 1,* 1 CICECO–Aveiro Institute of Materials, Chemistry Department, University of Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal; [email protected] (L.S.C.); [email protected] (G.S.L.); [email protected] (M.G.F.) 2 Centre for Mechanical Engineering, Materials and Processes, Department of Chemical Engineering, University of Coimbra, Rua Sílvio Lima-Polo II, 3030-790 Coimbra, Portugal; [email protected] * Correspondence: [email protected] (M.C.N.); [email protected] (A.Q.P.) † These authors contributed equally to this work. Abstract: The advent of biopharmaceuticals in modern medicine brought enormous benefits to the treatment of numerous human diseases and improved the well-being of many people worldwide. First introduced in the market in the early 1980s, the number of approved biopharmaceutical products has been steadily increasing, with therapeutic proteins, antibodies, and their derivatives accounting for most of the generated revenues. The success of pharmaceutical biotechnology is closely linked with remarkable developments in DNA recombinant technology, which has enabled the production of proteins with high specificity. Among promising biopharmaceuticals are interferons, first described by Isaacs and Lindenmann in 1957 and approved for clinical use in humans nearly thirty years later. Interferons are secreted autocrine and paracrine proteins, which by regulating several biochemical Citation: Castro, L.S.; Lobo, G.S.; pathways have a spectrum of clinical effectiveness against viral infections, malignant diseases, Pereira, P.; Freire, M.G.; Neves, M.C.; and multiple sclerosis.
    [Show full text]
  • 7 Engineering of Therapeutic Proteins
    Engineering of 7 Therapeutic Proteins Fei Wen, Sheryl B. Rubin-Pitel, and Huimin Zhao CONTENTS Protein Therapeutics versus Small Molecule Drugs .............................................. 154 Sources of Protein Therapeutics ................................................................... 155 Targets of Protein Therapeutics and Modes of Action .................................. 155 Engineering Effective Protein Therapeutics .......................................................... 156 Challenges in Pharmaceutical Translation of New Therapeutic Proteins ..... 156 Strategies for Designing Effective Protein Therapeutics .............................. 156 Strategies for Improving Pharmacokinetics ...................................... 157 Strategies for Reducing Immunogenicity ......................................... 158 Genetic Engineering ......................................................................... 159 Examples of Protein Therapeutics ......................................................................... 160 Monoclonal Antibody Therapeutics.............................................................. 161 Enzyme Therapeutics Acting on Extracellular Targets ................................. 161 Protein Therapeutics as Replacements for Defective or Deficient Proteins .....162 Protein Hormones ............................................................................. 162 Coagulation Factors .......................................................................... 163 Enzyme Replacement Therapy ........................................................
    [Show full text]
  • Part One General Information
    1 Part One General Information 3 1 Half - Life Modulating Strategies – An Introduction Roland E. Kontermann 1.1 Therapeutic Proteins With roughly 200 biologics approved for therapeutic applications and more than 600 under clinical development [1] , biotechnology products cover an increased proportion of all therapeutic drugs. Besides monoclonal antibodies and vaccines, which account for more than two - thirds of these produces, hormones, growth factors, cytokines, fusion proteins, coagulation factors, enzymes and other pro- teins are listed. An overview of the different classes of currently approved protein therapeutics is shown in Table 1.1 . Except for antibodies and Fc fusion proteins, many of these proteins possess a molecular mass below 50 kDa and a rather short terminal half - life in the range of minutes to hours. In order to maintain a thera- peutically effective concentration over a prolonged period of time, infusions or frequent administrations are performed, or the drug is applied loco - regional or subcutaneously utilizing a slow adsorption into the blood stream. These limita- tions of small size protein drugs has led to the development and implementation of half - life extension strategies to prolong circulation of these recombinant anti- bodies in the blood and thus improve administration and pharmacokinetic as well as pharmacodynamic properties. 1.2 Renal Clearance and F c R n - Mediated Recycling The effi cacy of protein therapeutics is strongly determined by their pharmacoki- netic properties, including their plasma half - lives, which infl uence distribution and excretion. Although a small size facilitates tissue penetration, these molecules are often rapidly cleared from circulation. Thus, they have to be administered as infusion or repeated intravenous ( i.v.
    [Show full text]
  • Interferon in Inflammatory Diseases
    Meeting report Lupus Sci Med: first published as 10.1136/lupus-2018-000276 on 15 June 2018. Downloaded from Report of the inaugural Interferon Research Summit: interferon in inflammatory diseases Mary K Crow,1 Lars Rönnblom2 To cite: Crow MK, ABSTRACT responses to distinct classes of therapeutic Rönnblom L. Report of An international summit agents. the inaugural Interferon on interferon (IFN) in inflammatory diseases, held in The inaugural International Summit on Research Summit: interferon Gaithersburg, Maryland, USA (4–5 May 2017), united 22 in inflammatory diseases. IFN in Inflammatory Diseases united 22 inter- internationally renowned clinicians and scientists with Lupus Science & Medicine nationally renowned clinicians and scientists backgrounds in basic science, translational science and 2018;5:e000276. doi:10.1136/ with backgrounds in basic science, transla- lupus-2018-000276 clinical medicine. The objectives of the summit were to assess the current knowledge of the role of type I IFN in tional science and clinical medicine. Goals inflammatory diseases and other conditions, discuss the of the summit included assessing the current ► Additional material is available clinical trial data of anti-IFN therapeutic agents knowledge of the role type I IFN plays in published online only. To view and identify key clinical and therapeutic knowledge gaps inflammatory diseases and other conditions, please visit the journal online (http:// dx. doi. org/ 10. 1136/ 10. and future directions to advance the treatment landscape discussing available clinical data examining 1136/ lupus- 2018- 000276) of diseases involving the type I IFN pathway. A discussion- anti-IFN therapies and identifying current key based consensus process was used to assess three main clinical and therapeutic knowledge gaps.
    [Show full text]
  • Translational Genomics, Transcriptomics and Metabolomics Analyses of the Metabolic Effects of Chronic Hepatitis C Infection and Their Clinical Implications
    Translational genomics, transcriptomics and metabolomics analyses of the metabolic effects of chronic hepatitis C infection and their clinical implications. Dr Paul J Clark MBBS (Hons I), MPH&TM, FRACP A thesis in fulfilment of the requirements for the degree of Doctor of Philosophy Kirby Institute for Infection and Immunity in Society Faculty of Medicine The University of New South Wales, Sydney, Australia August 2012 THE UNIVERSITY OF NEW SOUTH WALES Thesis/Dissertation Sheet Surname or Family name: CLARK First name: Paul Other name/s: James Abbreviation for degree as given in the University calendar: PhD School: The Kirby Institute Faculty: Medicine Title: Translational genomics, transcriptomics and metabolomics analyses of the metabolic effects of chronic hepatitis C infection and their clinical implications. Abstract 350 words maximum: (PLEASE TYPE) Background: The hepatitis C virus (HCV) relies on host lipid pathways for its life cycle, leading to metabolic consequences including hypocholesterolemia, insulin resistance and hepatic steatosis. These sequelae have varying clinical implications, including poorer sustained viral response (SVR) to pegylated interferon/ribavirin (PEG/RBV) therapy, increased risk of hepatic fibrosis and residual risk of liver disease (eg fibrosis, steatosis) and complications (eg hepatocellular carcinoma), even after SVR. Aims: To define host genomic and metabolomic profiles associated with hypocholesterolemia, hepatic steatosis, hepatic fibrosis and hepatic inflammation in chronic HCV infection, and to assess their clinical impacts. Methods: Genome wide association studies, candidate gene studies, microarray based mRNA transcription profiling, liquid chromatography/mass spectrometry metabolomic assays, multivariable regression models (MVR). Results: In HCV genotype 1 (G1), IL28B genotype is the only common variant associated with LDL-C levels.
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) FORMER DOCUMENT NUMBER: INN Working Document 05.179 © World Health Organization 2019 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • A Potent in Vivo Antitumor Efficacy of Novel Recombinant Type I Interferon
    Published OnlineFirst September 28, 2016; DOI: 10.1158/1078-0432.CCR-16-1386 Cancer Therapy: Preclinical Clinical Cancer Research A Potent In Vivo Antitumor Efficacy of Novel Recombinant Type I Interferon Kang-Jian Zhang1,2,3, Xiao-Fei Yin1, Yuan-Qin Yang1,4, Hui-Ling Li1, Yan-Ni Xu1, Lie-Yang Chen1, Xi-Jun Liu1, Su-Jing Yuan1, Xian-Long Fang1, Jing Xiao1, Shuai Wu1, Hai-Neng Xu1,5, Liang Chu1, Kanstantsin V. Katlinski2, Yuliya V. Katlinskaya2, Rong-Bing Guo3, Guang-Wen Wei3, Da-Cheng Wang6, Xin-Yuan Liu1,4, and Serge Y.Fuchs2 Abstract Purpose: Antiproliferative, antiviral, and immunomodulatory Results: sIFN-I displayed greater affinity for IFNAR1 (over activities of endogenous type I IFNs (IFN1) prompt the design of IFNAR2) chain of the IFN1 receptor and elicited a greater recombinant IFN1 for therapeutic purposes. However, most of the extent of IFN1 signaling and expression of IFN-inducible designed IFNs exhibited suboptimal therapeutic efficacies against genes in human cells. Unlike IFNa-2b, sIFN-I induced solid tumors. Here, we report evaluation of the in vitro and in vivo JAK–STAT signaling in mouse cells and exhibited an extend- antitumorigenic activities of a novel recombinant IFN termed sIFN-I. ed half-life in mice. Treatment with sIFN-I inhibited intra- þ Experimental Design: We compared primary and tertiary tumoral angiogenesis, increased CD8 T-cell infiltration, and structures of sIFN-I with its parental human IFNa-2b, as well as robustly suppressed growth of transplantable and genetically affinities of these ligands for IFN1 receptor chains and pharma- engineered tumors in immunodeficient and immunocompe- cokinetics.
    [Show full text]
  • Randomized Trial of Albinterferon Alfa2b Every 4Weeks for Chronic
    Journal of Viral Hepatitis, 2012, 19, 623–634 doi:10.1111/j.1365-2893.2012.01586.x Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3 S. Pianko,1 S. Zeuzem,2 W.-L. Chuang,3 G. R. Foster,4 S. K. Sarin,5 R. Flisiak,6 C.-M. Lee,7 P. Andreone,8 T. Piratvisuth,9 S. Shah,10 A. Sood,11 J. George,12 M. Gould,13 P. Komolmit,14 S. Thongsawat,15 T. Tanwandee,16 J. Rasenack,17 Y. Li,18 M. Pang,19 Y. Yin,19 G. Feutren20 21 and I. M. Jacobson for the B2202 Study Team 1Monash Medical Centre and Monash University, Melbourne, Vic., Australia; 2J.W. Goethe University Hospital, Frankfurt, Germany; 3Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; 4Queen MaryÕs University of London, Blizard Institute of Cell and Molecular Science, London, UK; 5Department of Hepatology, Institute of Liver and Biliary Sciences, G B Pant Hospital, Delhi, India; 6Medical University of Bialystok, Bialystok, Poland; 7Chang Gung Memorial Hospital–Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan; 8Department of General Surgery and Organ Transplantation, Alma Mater Studiorum–Universita` di Bologna, Azienda Ospedaliero–Universitaria Policlinico S. Orsola–Malpighi, Bologna, Italy; 9Department of Internal Medicine, NKC Institute of Gastroenterology and Hepatology, Songklanagarind Hospital, Prince of Songkla University, Hat Yai, Thailand; 10Jaslok Hospital and Research Centre, Mumbai, India; 11Department of Gastroenterology, Dayanand Medical College & Hospital,
    [Show full text]
  • International Nonproprietary Names (INN) for Biological and Biotechnological Substances
    WHO/EMP/RHT/TSN/2014.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) WHO/EMP/RHT/TSN/2014.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) FORMER DOCUMENT NUMBER: INN Working Document 05.179 © World Health Organization 2014 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int ) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected] ). Requests for permission to reproduce or translate WHO publications –whether for sale or for non- commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html ). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Statistical Analysis Plan P15-698
    HCV RWE PMOS Statistical Analysis Plan P15-698 NCT02807402 Version 1.0 STATISTICAL ANALYSIS PLAN STUDY P15-698 Version 1.0 28 July 2017 RWE_SAP_RO_2017-07-28_V1-0.docx Page 1 of 50 HCV RWE PMOS Statistical Analysis Plan P15-698 Version 1.0 General Information Protocol Real World Evidence of the Effectiveness of Paritaprevir/r – Ombitasvir, + Dasabuvir, ± Ribavirin in Patients with Chronic Hepatitis C - An Observational Study in Romania P15-698 Document Statistical Analysis Plan (SAP) – Version 1.0. definition 28 July 2017 Related Study Protocol, dated 16 March 2016 Documents Document IST GmbH, owner RWE_SAP_RO_2017-07-28_V1-0.docx Page 2 of 50 HCV RWE PMOS Statistical Analysis Plan P15-698 Version 1.0 TABLE OF CONTENTS Page 1. INTRODUCTION .........................................................................................................................8 2. STUDY OBJECTIVES ....................................................................................................................8 3. STUDY DESIGN ...........................................................................................................................9 3.1 Overview of Study Design and Dosing Regimen ....................................................9 3.2 Sample Size Calculation ...................................................................................... 10 4. STATISTICAL CONSIDERATIONS AND ANALYTICAL PLAN ........................................................ 11 4.1 Primary and Secondary Parameters ..................................................................
    [Show full text]
  • Dysregulation of Innate Immunity in Hepatitis C Virus Genotype 1 IL28B-Unfavorable Genotype Patients: Impaired Viral Kinetics and Therapeutic Response
    Dysregulation of Innate Immunity in Hepatitis C Virus Genotype 1 IL28B-Unfavorable Genotype Patients: Impaired Viral Kinetics and Therapeutic Response Susanna Naggie,1* Anu Osinusi,2,3* Antonios Katsounas,3 Richard Lempicki,3 Eva Herrmann,4 Alexander J. Thompson,1 Paul J. Clark,1 Keyur Patel,1 Andrew J. Muir,1 John G. McHutchison,5 Joerg F. Schlaak,6 Martin Trippler,6 Bhavana Shivakumar,2 Henry Masur,7 Michael A. Polis,2 and Shyam Kottilil2 Recent studies have shown that a single-nucleotide polymorphism upstream of the interleukin- 28B (IL28B) gene plays a major role in predicting therapeutic response in hepatitis C virus (HCV)-infected patients treated with pegylated interferon (PEG-IFN)/ribavirin. We sought to investigate the mechanism of the IL28B polymorphism, specifically as it relates to early HCV viral kinetics, IFN pharmacokinetics, IFN pharmacodynamics, and gene expression profiles. Two prospective cohorts (human immunodeficiency virus [HIV]/HCV-coinfected and HCV-monoinfected) completing treatment with IFN/ribavirin were enrolled. Patients were gen- otyped at the polymorphic site rs12979860. In the HIV/HCV cohort, frequent serum sampling was completed for HCV RNA and IFN levels. DNA microarray of peripheral blood mononu- clear cells and individual expression of IFN-stimulated genes (ISGs) were quantified on IFN therapy. The IL28B-favorable (CC) genotype was associated with improved therapeutic response compared with unfavorable (CT or TT) genotypes. Patients with a favorable genotype had greater first- and second-phase viral kinetics (P 5 0.004 and P 5 0.036, respectively), IFN maximum antiviral efficiency (P 5 0.007) and infected cell death loss (P 5 0.009) compared with unfavorable genotypes.
    [Show full text]